重组人血栓调节蛋白用于合并肿瘤急症的弥散性血管内凝血外科患者的临床疗效
[Clinical Efficacy of Recombinant Human Thrombomodulin for Surgical Patients with Disseminated Intravascular Coagulation Associated with Oncologic Emergency].
作者信息
Ikuta Lisa, Nakajima Takayoshi, Fujikawa Masataka, Nomura Kazunori, Matsuki Goshi, Ichise Noriko, Kasai Meidai, Okamoto Ryo, Ikuta Shinichi, Nakamoto Yoshihiko, Aihara Tsukasa, Yanagi Hidenori, Yamanaka Naoki
机构信息
Dept. of Surgery, Meiwa Hospital.
出版信息
Gan To Kagaku Ryoho. 2022 Dec;49(13):1408-1410.
AIM
We evaluated the clinical efficacy of recombinant human thrombomodulin(rTM)for surgical patients with disseminated intravascular coagulation syndrome(DIC)associated with an oncologic emergency(OE).
SUBJECTS AND METHODS
Thirteen patients who underwent surgery for OE complicated with DIC and were treated with rTM in our institution were evaluated. We retrospectively analyzed the clinical changes of parameters in white blood cell count(WBC), platelet count, CRP, PT-INR and DIC scores after the rTM treatment.
RESULTS
The average length of the days using rTM was 4.7 for 12 patients, excluding one who died within 30 days after surgery. Nine of 12 patients(75%)had DIC scores of less than 3 after the rTM treatment. WBC tended to decrease after the rTM treatment, without statistical difference. However, CRP, platelet count, PT-INR and DIC scores were significantly improved after the rTM treatment(p<0.05).
CONCLUSIONS
rTM may be useful in the treatment of DIC for surgical OE patients.
目的
我们评估了重组人血栓调节蛋白（rTM）对患有与肿瘤急症（OE）相关的弥散性血管内凝血综合征（DIC）的外科手术患者的临床疗效。
对象与方法
对我院13例因OE并发DIC而接受手术并接受rTM治疗的患者进行评估。我们回顾性分析了rTM治疗后白细胞计数（WBC）、血小板计数、CRP、PT-INR和DIC评分等参数的临床变化。
结果
12例患者使用rTM的平均天数为4.7天，其中1例患者在术后30天内死亡。12例患者中有9例（75%）在rTM治疗后DIC评分小于3。rTM治疗后WBC有下降趋势，但无统计学差异。然而，rTM治疗后CRP、血小板计数、PT-INR和DIC评分均有显著改善（p<0.05）。
结论
rTM可能对外科OE患者DIC的治疗有用。
Zotero 插件